Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Molecular Factors Associated With Minimal Residual Disease in Newly Diagnosed Multiple Myeloma After Quadruplet Therapy

  • By

  • Florence Magrangeas

  • Mia Cherkaoui

  • Victor Bessonneau-Gaborit

  • Jennifer Derrien

  • Céline Chevalier

  • Catherine Guérin-Charbonnel

  • Benjamin Diamond

  • Mehmet Kemal Samur

  • Cyrille Hulin

  • Denis Caillot

  • Lionel Karlin

  • Bertrand Arnulf

  • Ola Landgren

  • Nikhil C. Munshi

  • Hervé Avet-Loiseau

  • Ludovic Martinet

  • Jill Corre

  • Aurore Perrot

  • Philippe Moreau

  • Cyrille Touzeau

  • Stéphane Minvielle

  • Eric Letouzé

  • October 19, 2026

Share

  • 1

    The MIDAS ancillary study profiled 423 newly diagnosed multiple myeloma cases using whole-genome sequencing, RNA sequencing, and DNA methylation sequencing.

  • 2

    The cohort received standardized induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone; MRD predictor analyses were restricted to enrolled patients.

  • 3

    Gene expression analysis identified eight molecular groups associated with genomic alterations, including three distinct hyperdiploid subgroups.

  • 4

    Among 368 enrolled patients with postinduction MRD data, 44.8% were MRD negative at 10−6 and 59.8% at 10−5.

  • 5

    MRD-negativity rates differed significantly by expression group, with the lowest rates in CD2 and MF and the highest in HP1, HP3, and MS.

Original Source(s)

Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

  • by Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Benjamin Diamond, Mehmet Kemal Samur, Cyrille Hulin, Denis Caillot, Lionel Karlin, Bertrand Arnulf, Ola Landgren, Nikhil C. Munshi, Hervé Avet-Loiseau, Ludovic Martinet, Jill Corre, Aurore Perrot, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle, Eric Letouzé

  • October 19, 2026

Related Content

CRISPR-Based Delivery System Generates CAR T Cells In Vivo

A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models

  • October 13, 2026

  • 3 min
2026 ASCO Breast Cancer Highlights: BWEL

Harold Burstein, MD, PhD, and Jennifer A. Ligibel, MD discuss new research from the Breast Cancer Weight Loss (BWEL) trial, as well as recommendations for lifestyle, diet and GLP1 agonists.

  • October 15, 2026

  • 1 min
Expanding surgical options for liver cancer and liver metastases

Advances in minimally invasive surgery and liver-directed therapies at UCI Health offer new treatment for complex liver malignancies.

  • October 14, 2026

  • 2 min